Etbicyphat - Moligand™, 10 mM in DMSO , CAS No.1005-93-2

CAS: 1005-93-2 Cat. No.: E1496761 Fórmula: C6H11O4P Peso molecular: 178.12 Beilstein Registry Number: 1909748 Número EC: 213-740-6
Disponible para pedir
CALIDAD & PUREZA Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools. 10 mM in DMSO
Storage
Protected from light,Store at -80°C
Shipped In
Dry ice packs + Cold packs
★
Talla
Alemania (EU)
USA*
Precio
Cantidad
1ml
E1496761-1ml
Fabricado bajo pedido · 8–12 semanas
51,11€
Enter a quantity for the sizes you want to add.

Descripción general

Etbicyphat (Trimethylopropane phosphate) is a potent GABA(A) receptors competitive antagonist. Etbicyphat induces epileptiform activities in hippocampal CA1 neurons, and binds to the GABA(A)-benzodiazepine receptors.

Especificaciones

Especificaciones y pureza
Moligand™, 10 mM in DMSO
Condiciones de almacenamiento de almacenamiento
Protected from light,Store at -80°C
Enviado en
Dry ice packs + Cold packs
Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.
Grado
Moligand™
Tipo de acción
ANTAGONIST
Nombres e identificadores
Isómeros SMILES
CCC12COP(=O)(OC1)OC2
WGK Alemania
3
RTECS
TY6475000
Peso molecular
178.12
Beilstein
1909748
Reaxys
1909748
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=1909748&ln=

Datos avanzados

Certificados (CoA, COO, BSE/TSE y tabla de análisis)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Propiedades químicas y físicas
Índice de refracciónn20D1.47
Punto de ebullición (°C)~213.1° C at 760 mmHg (Predicted)
Punto de fusión (°C)201-202° C
Seguridad y peligros (GHS)
WGK Alemania
3
RTECS
TY6475000
Reaxys
1909748
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=1909748&ln=
Calculadoras de soluciones
Reseñas

Reseñas de cliente

Application Protocols

General protocols for small-molecule screening compounds (adapt as needed):

  • DMSO stock preparation

    1. Allow vial to equilibrate briefly on ice or at 4 °C to avoid condensation; keep protected from light.
    2. Weigh the compound quickly to minimize moisture uptake (if applicable). Dissolve in anhydrous DMSO to 10–50 mM.
    3. Vortex until homogeneous. If needed, brief bath sonication can aid dissolution. Avoid elevated temperatures without stability data.
    4. Dispense into single-use aliquots (low-bind tubes), flush headspace with dry inert gas if available, cap tightly, and freeze at −80 °C.
  • Plate handling for HTS

    • Thaw aliquots on ice, keep protected from light, and centrifuge briefly to collect condensate.
    • Use acoustic or pintool transfer to minimize DMSO volume. Aim for final DMSO ≤0.5–1% v/v; include matched vehicle controls.
    • After dilution into assay buffer/cell media, visually confirm absence of precipitation; consider pre-wetting tips to reduce adsorption.
  • Orthogonal/biophysical assays

    • For DSF/thermal shift, maintain consistent DMSO across wells. For SPR/MST, filter and degas buffers; verify compound does not aggregate or fluoresce in the detection window.

These are general recommendations. Optimize for your assay format and confirm compatibility empirically.

Biological Roles
  • Item-specific biological function, targets, or pathways: Not specified for this item; refer to primary literature or internal screening data if available.
  • General context
    • As a Moligand™ library member, Etbicyphat is intended for use as a research tool in discovery biology and chemical biology to explore structure–activity relationships (SAR), identify preliminary hits, or serve as a reference chemotype in profiling experiments.
    • Without a confirmed mechanism or annotated target, it should be treated as a chemical matter starting point. Follow-up studies (counterscreens, orthogonal assays, and artifact mitigation such as aggregation and redox activity checks) are recommended before drawing biological conclusions.
  • Data provenance
    • Use the CAS (1005-93-2) or PubChem CID (13869) to query databases for any reported biochemical annotations; verify identity and form with the item’s CoA before extrapolating literature data to this specific lot.

Note: No medical or clinical claims are made. This product is for research use only.

Buffer Applications

Etbicyphat is not a buffering agent and is not typically used to prepare pH buffer systems.

  • Practical guidance
    • If used in aqueous assays, dissolve first in DMSO to prepare a concentrated stock, then dilute into the assay buffer of choice (e.g., HEPES, PBS, Tris) while keeping final organic content low (commonly ≤0.5–1% v/v).
    • Confirm that the buffer components do not chemically react with the compound (e.g., avoid reactive amines or nucleophiles if the scaffold is electrophile-sensitive—verify once structure is confirmed from CoA).

For dedicated buffer formulation information, consult the documentation for standard buffering agents rather than this small molecule.

Green Alternatives

Because Etbicyphat is supplied as a discovery library small molecule rather than a process solvent or commodity reagent, “green alternatives” apply mainly to the choice of handling solvents and formulation strategies.

  • Greener handling options (general guidance)
    • Prefer water-rich systems when feasible (buffer with minimal DMSO, ≤0.1–0.5% v/v) while maintaining solubility and assay integrity.
    • Consider 2-methyltetrahydrofuran (2-MeTHF) or cyclopentyl methyl ether (CPME) as greener alternatives during any synthetic modification steps (if you derivatize the scaffold), replacing traditional chlorinated or petroleum ether solvents where compatible.
    • For preparative workups, reduce halogenated solvent usage and implement solvent recycling.
  • Trade-offs
    • Lower-toxicity solvents may provide reduced solubilization for highly lipophilic compounds, requiring co-solvents or longer dissolution times.
    • Water-rich systems can introduce colloids/aggregation; include detergent controls and aggregation counterscreens.

Small comparison (general, for dissolution)

  • DMSO: Excellent solubilizer; not particularly green but used at very low volumes in assays.
  • Ethanol: Greener profile; volatility may complicate accurate dosing.
  • PEG400/water: Improved safety; viscosity and assay interference possible.

Always re-validate assay performance when changing solvent systems.

Pharmaceutical Uses
  • Regulatory/excipient status: Not specified for this item; no pharmacopeial status provided. This product is sold strictly for research use only.
  • Formulation role (research context only)
    • In discovery and preclinical research settings, small molecules like Etbicyphat are commonly formulated as DMSO stocks and diluted into in vitro systems. For in vivo research formulation development (if applicable and permitted within your institution), vehicles such as PEG400/saline, Captisol, or Tween-containing aqueous systems may be evaluated; ensure full compliance with local regulations and ethical approvals.
  • Manufacturing/CMC considerations (general)
    • If scale-up or salt screening is contemplated for research, confirm solid form, polymorph/solvate state, and stability under humidity/light. None of these parameters are specified for this item and must be determined experimentally.

No therapeutic claims are made or implied. This material is not intended for human or veterinary use.

Physical Properties
  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Melting point / Boiling point: Not specified for this item; refer to CoA/Spec Sheet.
  • Density, refractive index: Not specified for this item; refer to CoA/Spec Sheet.
  • pKa / logP (literature/computed): Not provided here. For in silico planning, retrieve from cheminformatics resources using CAS 1005-93-2 or PubChem CID 13869 and confirm experimentally.
  • Solubility profile (general guidance, not item-specific specs)
    • For small-molecule screening solids, initial dissolution is typically attempted in anhydrous DMSO to prepare concentrated stocks (e.g., 10–50 mM), followed by dilution into assay buffers.
    • If DMSO is insufficient, co-solvents such as DMF or ethanol can be explored, or solubilization aids (cyclodextrins, mild surfactants) may be employed. Verify compatibility with your assay.
  • Hygroscopicity/volatility: Not specified for this item; refer to CoA/Spec Sheet.

Important notes

  • Do not treat the above general dissolution comments as specifications. Confirm actual solubility and stability experimentally on receipt.
  • Always verify physical constants (MP/BP, pKa, logP) from primary literature or validated databases and reconcile with the supplied CoA for this specific lot.
Quality and Grades
  • Item-specific grade: Moligand™ (from Product Data)
    • Moligand™ denotes inclusion in a small-molecule/ligand screening collection intended for discovery research.
    • Primary emphasis typically includes identity confirmation and suitability for high-throughput screening workflows. Exact acceptance criteria (e.g., purity thresholds, analytical methods) are not specified for this item; refer to CoA/Spec Sheet.
  • What the grade generally implies (general information)
    • Library-grade compounds are commonly supplied to enable reliable stock solution preparation (e.g., DMSO stocks) and plate-based assays.
    • Analytical characterization for such collections often involves orthogonal identity checks (e.g., MS) and purity assessment; however, do not assume a particular technique or threshold without the item’s CoA.
  • Stabilizers and additives
    • None stated for this item. If stabilizers or counter-ions are present, they will be listed on the CoA/Spec Sheet.
  • UV cutoff, metal limits, residual solvents
    • Not specified for this item; refer to CoA/Spec Sheet.

Recommendations

  • On receipt, document lot number, review the CoA, and, if your workflow is purity-sensitive (e.g., biophysical binding, crystallography), consider in-house verification (LC–MS/HPLC-NMR) prior to HTS/validation studies.
Reaction and Applications

This product is positioned as a Moligand™ small-molecule for discovery workflows rather than as a synthetic reagent. Accordingly, applications emphasize screening and profiling rather than serving as a reaction solvent or building block.

  • Discovery and screening use-cases (general)
    • High-throughput screening (HTS) and hit identification across biochemical, biophysical, or cell-based assays.
    • Orthogonal confirmation studies (e.g., thermal shift/DSF, SPR, MST) where concentrated DMSO stocks are serially diluted into assay buffers.
    • Mechanism-of-action follow-up via chemoinformatics (similarity searches, substructure queries) using CAS 1005-93-2 or PubChem CID 13869 to identify related chemotypes.
  • Practical tips
    • Prepare fresh DMSO stocks at known concentration (e.g., 10–50 mM), verify by weight/volume and, when critical, by quantitative NMR or UV if the extinction coefficient is known (not provided here).
    • Filter stocks (0.2 µm PTFE) if particulate persists after dissolution; avoid adsorption by using low-bind plastics or glass.
    • Include vehicle controls at the same final DMSO percentage as treated wells.
  • Not a typical synthetic reagent
    • No named-reaction roles or catalyst applications are indicated for this item. If used in chemical biology derivatization (e.g., probe development), verify functional group compatibility and obtain the full structural information from the CoA before planning transformations.
Reaction Conditions

This section is interpreted for assay preparation and handling rather than chemical transformations, given the Moligand™ context.

  • Stock solution preparation (general guidance)
    • Weigh accurately and dissolve in anhydrous DMSO to 10–50 mM. Vortex and sonicate gently if needed. Avoid heating unless stability is known.
    • Filter through 0.2 µm PTFE if particulates persist. Use amber vials to protect from light (storage guidance below).
  • Assay dilution
    • Typical final vehicle content: 0.1–1% DMSO v/v in biochemical/cell assays; verify assay tolerance and include vehicle controls.
    • Mix thoroughly upon dilution to minimize precipitation; inspect wells for turbidity or edge effects.
  • Stability checks
    • Perform short-term stability tests of working solutions at assay temperature. If signal drift or potency loss is observed, prepare fresh dilutions immediately before use.
  • Analytical confirmation
    • Where results are decision-critical, confirm concentration by qNMR or UV (only if an extinction coefficient is reliably known; not provided here). LC–MS can be used to monitor integrity during assay runs.

Note: No reaction temperatures, catalysts, or yields are provided for chemical synthesis of this specific compound; consult literature once the full structure is confirmed.

Safety and Handling
  • GHS classification, signal word, pictograms, and H-statements: Not specified for this item; refer to the product SDS for authoritative safety information.
  • Storage conditions (from Product Data)
    • Store at −80 °C.
    • Protect from light.
  • Shipping (from Product Data)
    • Shipped on dry ice packs + cold packs to maintain low temperature and mitigate thermal excursions.
  • General laboratory precautions (applicable to small-molecule research compounds)
    • Handle in a fume hood or well-ventilated area; avoid inhalation of dust/aerosols.
    • Wear appropriate PPE: lab coat, safety glasses, and suitable chemical-resistant gloves.
    • Avoid skin/eye contact; prevent ingestion. Wash thoroughly after handling.
  • Incompatibilities and stability (general guidance)
    • Until specific data are available, avoid strong oxidizers/reducers and extremes of pH. Minimize exposure to moisture, heat, and light.
    • Prepare single-use aliquots to limit freeze–thaw cycles, which can accelerate degradation.
  • First-aid overview (consult SDS for full instructions)
    • Inhalation: Move to fresh air; seek medical attention if symptoms occur.
    • Skin/eyes: Rinse with copious water for at least 15 minutes; remove contaminated clothing; obtain medical advice.
    • Ingestion: Rinse mouth; seek medical attention. Do not induce vomiting unless directed by medical personnel.

Defer to the SDS for hazard classification, exposure limits, spill response, and disposal procedures specific to this material.

Solvent Selection

Practical solvent selection for small-molecule screening solids (general, not item-specific specifications):

  • Primary vehicle
    • DMSO (anhydrous) is the default for preparing concentrated stocks (e.g., 10–50 mM) owing to broad solubilization capacity and compatibility with most assay formats.
  • Secondary/co-solvents
    • DMF and ethanol can be explored for pre-dissolution; final assay media should limit organic content (commonly ≤0.5–1% v/v DMSO-equivalent) to avoid assay artifacts.
  • Aqueous delivery
    • For poor aqueous compatibility, consider co-solvent dilution, pH adjustment when chemically appropriate (if the compound is ionizable; verify first), or solubilization aids (hydroxypropyl-β-cyclodextrin, low % nonionic surfactants). Confirm no interference with readout.
  • Selection considerations
    • Enzymatic assays: Favor minimal organic content and validated vehicles; pre-screen vehicle effects.
    • Cell-based assays: Keep DMSO ≤0.1–0.5% where possible; include vehicle controls on every plate.
  • Comparison snapshot (general)
    • DMSO: Highest solvating power; may affect some targets at >1%.
    • DMF: Strong solvent; higher cytotoxicity risk in cells.
    • Ethanol: Volatile; limited solubilization for highly lipophilic compounds.
    • PEG400/water blends: Useful for in vivo formulation research (not for clinical use); viscosity can complicate pipetting.

Always validate solubility and stability of Etbicyphat experimentally under your exact assay conditions.

Storage and Reconstitution
  • Storage conditions (item-specific; from Product Data)

    • Store at −80 °C.
    • Protect from light (use amber containers/foil wrap).
  • Shipping (item-specific; from Product Data)

    • Shipped on dry ice packs + cold packs to preserve low temperature during transit.
  • Reconstitution (general guidance, not a specification)

    • Solvent: Use anhydrous DMSO for initial stock preparation unless your internal data support an alternative.
    • Concentration: Commonly 10–50 mM for screening stocks; adjust based on solubility and assay needs.
    • Technique: Vortex to dissolve; if necessary, brief sonication. Avoid heat and prolonged exposure to ambient light.
    • Aliquoting: Prepare single-use aliquots to avoid repeated freeze–thaw. Store aliquots in airtight, low-bind, amber vials at −80 °C.
  • Stability and handling

    • Working solutions should be kept cold and protected from light; discard if precipitation, discoloration, or unexpected assay behavior is observed.
    • Long-term stability, water content, and impurity profiles are not specified for this item; refer to CoA/Spec Sheet and confirm in your lab.

For research use only. Verify all critical parameters (identity, purity, concentration, solubility) before high-value experiments.

Structure and Identity

Brief overview: Etbicyphat (SKU E1496761) is offered in Aladdin’s Moligand™ small‑molecule library format for research screening and discovery workflows.

  • Product identifiers
    • SKU: E1496761
    • Product name: Etbicyphat
    • CAS: 1005-93-2 (from Product Data)
    • PubChem CID: 13869 (from Product Data)
  • Registry and structure fields
    • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
    • InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
    • SMILES (canonical): Not specified for this item; refer to CoA/Spec Sheet.
  • Structural features (general note)
    • The detailed 2D/3D structure has not been provided in this listing. For computational or cheminformatics use (e.g., docking, similarity search), retrieve the canonical SMILES/InChI from primary databases using CAS 1005-93-2 or PubChem CID 13869, then verify against the Certificate of Analysis (CoA).
  • Stereochemistry and identifiers
    • Any stereochemical specification, salt/solvate form, or tautomeric preference: Not specified for this item; refer to CoA/Spec Sheet.

Distinction between data types:

  • Item-specific facts: Only the identifiers above (CAS, CID, SKU) are specified in Product Data.
  • Literature/computed values: Not provided here; consult peer-reviewed databases using CAS/CID and verify with the item’s CoA before use in regulated workflows.
Synthetic Utility

Etbicyphat is provided as a screening compound rather than a designated synthetic building block.

  • General notes on potential synthetic use
    • Without disclosed structure or functional group information in this listing, specific reactivity or transformation pathways cannot be advised. Obtain the structural data (SMILES/InChI) from the CoA or authoritative databases (CAS 1005-93-2; CID 13869) before planning derivatization or probe synthesis.
    • If later used as a starting point for SAR, typical medicinal chemistry operations may include selective functional group interconversions, heteroatom substitutions, or introduction of reporter handles (alkyne/azide) for chemoproteomics—contingent on the actual scaffold.
  • Reference standards
    • The compound may serve as an analytical reference for method development (LC–MS/UPLC) once purity and identity are confirmed.

Item-specific specifications such as reactive handles, protecting group strategies, and stability to acids/bases/oxidants are not provided and must be established experimentally.

Target Specificity
  • Target(s), pathway, or mode of action: Not specified for this item.
  • Antigen/epitope/clone/isotype: Not applicable (this is a small molecule, not an antibody or biological reagent).

Guidance

  • Treat Etbicyphat as an unannotated small molecule for exploratory screening. If literature indicates activity for CAS 1005-93-2 (PubChem CID 13869), verify that the structure, salt form, and purity match this item’s CoA before attributing any biological specificity.

¿Necesita ayuda para elegir la calidad?

Nuestra guía de selección de calidades cubre la pureza, el estado del estabilizador y la idoneidad de la aplicación para todas las variantes de nuestro catálogo.

Ver la guía de calidades Moligand™ →

¿Quieres que te enviemos un mensaje cuando tengamos descuentos disponibles?

Recordármelo más tarde

¡Gracias! Por favor, revisa tu bandeja de entrada de correo electrónico para confirmar.

¡Vaya! Las notificaciones están desactivadas.